text: The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of << navitoclax >>, a selective inhibitor of both BCL-2 and BCL-2-like 1 ([[ BCL-X(L) ]]), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.